bluebird bio Inc  

(Public, NASDAQ:BLUE)   Watch this stock  
Find more results for BLUE
+1.40 (0.85%)
Real-time:   2:29PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 165.65 - 169.60
52 week 56.80 - 169.60
Open 166.30
Vol / Avg. 278,857.00/798,039.00
Mkt cap 7.64B
P/E     -
Div/yield     -
EPS -7.01
Shares 45.83M
Beta 2.02
Inst. own 112%
Nov 30, 2017
bluebird bio Inc at Barclays Gene Editing and Gene Therapy Summit - 1:20PM EST - Add to calendar
Nov 29, 2017
bluebird bio Inc at Evercore ISI MedTools Conference - 12:50PM EST - Add to calendar
Nov 7, 2017
bluebird bio Inc at Credit Suisse Healthcare Conference - Webcast
Nov 1, 2017
Q3 2017 bluebird bio Inc Earnings Release
Nov 1, 2017
Q3 2017 bluebird bio Inc Earnings Call - Webcast
Oct 10, 2017
bluebird bio Inc at Chardan Inaugural Gene Therapy Conference
Sep 28, 2017
bluebird bio Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Sep 13, 2017
bluebird bio Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 7, 2017
bluebird bio Inc at Wells Fargo Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1021.98% -4281.19%
Operating margin -1007.11% -4351.42%
EBITD margin - -4193.83%
Return on average assets -22.08% -24.85%
Return on average equity -27.00% -30.64%
Employees 418 -
CDP Score - -


60 Binney St
CAMBRIDGE, MA 02142-1512
United States - Map
+1-339-4999300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Officers and directors

Daniel S. Lynch Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Nick Leschly President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Jeffrey T. Walsh Chief Financial and Strategy Officer and Principal Financial Officer, Principal Accounting Officer
Age: 51
Bio & Compensation  - Reuters
Susanna Gatti High Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Philip D. Gregory Ph.D. Chief Scientific Officer
Age: 46
Bio & Compensation  - Reuters
David M. Davidson M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Jason F. Cole Esq. Chief Legal Officer, Secretary
Age: 44
Bio & Compensation  - Reuters
John O. Agwunobi M.D. Director
Age: 52
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. Director
Age: 54
Bio & Compensation  - Reuters
Douglas A. Melton Director
Bio & Compensation  - Reuters